Our findings also demonstrate that loss of SETD1A represents a conserved mechanism of PARPi resistance across BRCA1- and ATM-deficient cancer cells (this study and [22]) but this is not extended to cells lacking BRCA2 (Figs. 1 and 2). This evidence concerns the gene BRCA2 and cancer.